After 20 years, Brazil resumes domestic insulin production

The Minister of Health, Alexandre Padilha , received this Friday 11, at the Biomm factory, in Nova Lima, Minas Gerais, the first batch of 100% national insulins , produced through Partnerships for Productive Development (PDP).

With the transfer of technology from the Indian pharmaceutical company Wockhardt, Brazil is once again manufacturing the drug, made possible by the public laboratory Fundação Ezequiel Dias (Funed) and the Brazilian company Biomm.

On that occasion, 207,385 units of the drug were delivered – 67,317 vials of regular insulin and 140,068 of NPH insulin. After the full transfer of technology, the Brazil will produce 50% of the demand related to NPH and regular insulin in the SUS , that is, around 45 million doses per year.

"About 10% of the Brazilian population has diabetes, and some of these people need to use insulin. This ensures peace of mind, safety, and stability for both the SUS and the citizens who depend on the medication," said Padilha.

With investments of 142 million reais in the acquisition of the technology, the contracts provide for the delivery of 8.01 million units of insulin to the public network, including vials and pens, in 2025 and 2026.